Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06034860 |
TitleStudy of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Phase
Phase 1
|
Date Added 2023-09-13 |
Location
California, United States
Indiana, United States Missouri, United States New York, United States Virginia, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
MT-8421, Nivolumab, Opdivo |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06026774 |
TitleClinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms | Phase
Phase 1
|
Date Added 2023-09-07 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06014502 |
TitleStudy to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2023-08-28 |
Location
Arizona, United States
California, United States Louisiana, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
IMGS-001 |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06013111 |
TitleAn Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2023-08-28 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06011772 |
TitleA Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | Phase
Early Phase 1
|
Date Added 2023-08-25 |
Location
New York, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06010901 |
TitleA Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. | Phase
Phase 1
|
Date Added 2023-08-25 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06008119 |
TitleEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Phase
Phase 3
|
Date Added 2023-08-23 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06006923 |
TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-08-23 |
Location
California, United States
Florida, United States Illinois, United States Michigan, United States Pennsylvania, United States Washington, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05999812 |
TitleClinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-08-21 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
all trans Retinoic Acid, Atezolizumab, Bevacizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT05990543 |
TitleCombination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2023-08-14 |
Location
South Korea
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nelmastobart and Capecitabine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|




